reports
- Jonathan Moreland
ZEUS OLYMPIC STEEL INC.
XOMA XOMA
NWBI NORTHWEST BANCSHARES INC.
NRIM NORTHRIM BANCORP INC.
MERC MERCER INTERNATIONAL INC.
MCY MERCURY GENERAL CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CRM SALESFORCE.COM INC.
CE CELANESE CORPORATION
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
AMH AMERICAN HOMES 4 RENT CLASS A
MGM MGM RESORTS INTERNATIONAL
OXM OXFORD INDUSTRIES INC.
RSG REPUBLIC SERVICES INC.
MHH MASTECH DIGITAL
WMG WARNER MUSIC GROUP CORP.
NHF NEXPOINT CREDIT STRATEGIES FUN
PMTS CPI CARD GROUP
NWPP NEW PEOPLES BANKSHARES INC.
MIDD THE MIDDLEBY CORPORATION
AVTR AVANTOR
SELF INC.
ALTG SELF STORAGE GROUP
IMVT INC.
ORIC ALTA EQUIPMENT GROUP INC.
NOG IMMUNOVANT INC
MRVI ORIC PHARMACEUTICALS
DMAC NORTHERN OIL AND GAS
AMR MARAVAI LIFESCIENCES HOLDINGS
NRDY DIAMEDICA THERAPEUTICS INC.
ABSI ALPHA METALLURGICAL RESOURCES INC
IMMX NERDY INC.
LUCY ABSCI CORP
LIN IMMIX BIOPHARMA INC
MNR INNOVATIVE EYEWEAR INC
XELB LINDE PUBLIC LIMITED COMPANY
FEAM MACH NATURAL RESOURCES LP
SEVN XCEL BRANDS INC.
5E ADVANCED MATERIALS INC.
SEVEN HILLS REALTY TRUST
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
MMLP MARTIN MIDSTREAM PARTNERS L.P.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CE CELANESE CORPORATION
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
OXM OXFORD INDUSTRIES INC.
MLP MAUI LAND & PINEAPPLE CO. INC.
WMG WARNER MUSIC GROUP CORP.
SPT SPROUT SOCIAL
IMVT INC.
NOG IMMUNOVANT INC
AMR NORTHERN OIL AND GAS
PBBK ALPHA METALLURGICAL RESOURCES INC
NRDY PB BANKSHARES
LUCY INC.
SMRT NERDY INC.
INNOVATIVE EYEWEAR INC
SMARTRENT INC
International Flavors & Fragrances Inc: 1 director
A director at International Flavors & Fragrances Inc bought 3,100 shares at 63.480USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Avalo Therapeutics Announces Inducement Grants to New Employees Under ...
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as indu...
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Re...
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team with key appointments in business development and human resourcesCash and short-term investments of approximately $112 million as of September 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechno...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Second Annual Healthcare Innovation ConferenceFireside ChatNovember 10, 2025, at 4:00 pm ET Stifel 2025 Healthcare ConferenceFireside ChatNovember 12, 2025, at 2:40 pm ET TD Cowen 1st Immunology & Inflamm...
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS...
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company has completed enrollment in its Phase 2 LOTUS trial of AVTX-009 in adults with hidradenitis suppurativa (HS). The LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enro...
LendingClub Corp: 1 director
A director at LendingClub Corp sold 30,000 shares at 19.290USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Avalo Therapeutics Expands Leadership Team with Key Appointments in Bu...
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. “We are delighted to welcome Taylor and Ashley to Aval...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TNDM TANDEM DIABETES CARE INC
RYAM RAYONIER ADVANCED MATERIALS INC
OPK OPKO HEALTH INC.
NEO NEOGENOMICS INC.
MTDR MATADOR RESOURCES COMPANY
KURA KURA ONCOLOGY INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
ICUI ICU MEDICAL INC.
EMN EASTMAN CHEMICAL COMPANY
EIG EMPLOYERS HOLDINGS INC.
D DOMINION ENERGY INC
COTY COTY INC. CLASS A
CNC CENTENE CORPORATION
CHD CHURCH & DWIGHT CO. INC.
ARW ARROW ELECTRONICS INC.
ALGN ALIGN TECHNOLOGY INC.
UPS UNITED PARCEL SERVICE INC. CLASS B
AROW ARROW FINANCIAL CORP.
KODK EASTMAN KODAK CO
AAOI APPLIED OPTOELECTRONICS INC.
ADC AGREE REALTY CORPORATION
HTLD HEARTLAND EXPRESS INC.
BSM BLACK STONE MINERALS LP
VVV VALVOLINE INC.
GBLI GLOBAL INDEMNITY PLC
FTV FORTIVE CORP.
SMRT SMARTSPACE SOFTWARE
CCEL CRYO-CELL INTERNATIONAL
SONO SONOS
ESTA ESTABLISHMENT LABS HOLDINGS
WU THE WESTERN UNION COMPANY
TROX TRONOX HOLDINGS PLC
LUMN LUMEN TECHNOLOGIES INC.
VTRS VIATRIS INC
ENVX ENOVIX CORP
PTLO PORTILLOS INC
EBC EASTERN BANKSHARES INC
MSDL MORGAN STANLEY DIRECT LENDING
BKKT BAKKT HOLDINGS INC.
FIP FTAI INFRASTRUCTURE INC
MRAI MARPAI
MDRR INC.
BOOM MEDALIST DIVERSIFIED REIT INC.
EFOI DYNAMIC MATERIALS CORPORATION
STSS ENERGY FOCUS INC.
SHARPS TECHNOLOGY INC.
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare ConferenceFireside ChatSeptember 3, 2025, at 2:10 pm ET H.C.Wainwright 27th Annual Global Investment ConferencePresentationSeptember 9, 2025, at 2:30 pm ET Stifel 2025 Virtual Immunology and...
- Jonathan Moreland
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TFX TELEFLEX INCORPORATED
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SHBI SHORE BANCSHARES INC.
PNFP PINNACLE FINANCIAL PARTNERS INC.
OPK OPKO HEALTH INC.
NSP INSPERITY INC.
NPO ENPRO INDUSTRIES INC.
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
LLY ELI LILLY AND COMPANY
KMPR KEMPER CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
EIG EMPLOYERS HOLDINGS INC.
CNOB CONNECTONE BANCORP INC.
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CHD CHURCH & DWIGHT CO. INC.
CDXS CODEXIS
ARW ARROW ELECTRONICS INC.
AMH AMERICAN HOMES 4 RENT CLASS A
CIVB CIVISTA BANCSHARES
OLN OLIN CORPORATION
ASUR ASURE SOFTWARE INC
BRO BROWN & BROWN INC.
CYRX CRYOPORT INC.
FTV FORTIVE CORP.
CLAR CLARUS CORPORATION
A2H9KJ NEO PERFORMANCE MATERIAL
OSPN ONESPAN
FXNC FIRST NATIONAL CORP. OF VIRGINIA
TROX TRONOX HOLDINGS PLC
MEC MAYVILLE ENGINEERING
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
XRX XEROX HOLDINGS CORPORATION
PINE ALPINE INCOME PROPERTY TRUST
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
LRMR LARIMAR THERAPEUTICS INC
THRY THRYV HOLDINGS
DLHC DALEIGH HOLDINGS CORP
INTA INTAPP INC
PTLO PORTILLOS INC
BRBR BELLRING BRANDS INC
AUB ATLANTIC UNION BANKSHARES CORP
AURX NUO THERAPEUTICS
OI INC.
SIRI OWENS ILLINOIS INC.
XELB SIRIUS XM HLDGS INC NEW
MUSA XCEL BRANDS INC.
LNW METALS USA HOLDINGS CORP.
LIGHT & WONDER INC.
- Jonathan Moreland
PNFP PINNACLE FINANCIAL PARTNERS INC.
OPK OPKO HEALTH INC.
NPO ENPRO INDUSTRIES INC.
LLY ELI LILLY AND COMPANY
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
BRO BROWN & BROWN INC.
CRSP CRISPR THERAPEUTICS AG
OSPN ONESPAN
TROX TRONOX HOLDINGS PLC
MEC MAYVILLE ENGINEERING
PINE ALPINE INCOME PROPERTY TRUST
PTLO PORTILLOS INC
AUB ATLANTIC UNION BANKSHARES CORP
LNW LIGHT & WONDER INC.
- Jonathan Moreland
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TFX TELEFLEX INCORPORATED
KMPR KEMPER CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
AMH AMERICAN HOMES 4 RENT CLASS A
OLN OLIN CORPORATION
CZWI CITIZENS COMMUNITY BANCORP
CLAR CLARUS CORPORATION
LOOP LOOP INDUSTRIES
FXNC FIRST NATIONAL CORP. OF VIRGINIA
TROX TRONOX HOLDINGS PLC
AUB ATLANTIC UNION BANKSHARES CORP
OI OWENS ILLINOIS INC.
Avalo Reports Second Quarter 2025 Financial Results and Recent Busines...
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113 million as of June 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, t...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences: HCW Annual Inflammation & Immunology Virtual ConferenceFireside ChatJune 30, 2025, at 11:00 am ET BTIG Virtual Biotechnology Conference 20251x1sJuly 29-30, 2025 Live webcasts and replays, when available, can be found under "News / Events" in the Investors secti...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board o...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. “We are pleased to welcome Dr. Jain to Avalo’s Board of Directors,” said Michael Heffernan, Chairman of the Board. “Rita’s extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biophar...
- Blair Levin
- Blair Levin
- Jonathan Chaplin
- Philip Burnett
Chapter 11 and Spectrum Values – Questions We Didn’t Get To
We hosted a call on Monday that covered our analysis of the impact of the FCC inquiries on spectrum values, and how this could change if the Company files for Chapter 11 protection. We hosted the call with Jeff Carlisle who is perhaps the leading expert on matters that sit at the intersection of telecom policy and bankruptcy. We got more questions than we could answer in the time we had, and so we covered the questions we didn’t get to in this note.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.